Skip to main content

Inhibikase Therapeutics, Inc 10-Q for FY2026 Q3

Inhibikase Therapeutics, Inc. (IKT)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Inhibikase Therapeutics, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$20.47M
compared with a net loss of $11.93M a year earlier
Diluted EPS
-$0.10
compared with -$0.13 a year earlier